10-Q: Mosaic ImmunoEngineering Reports Q1 2025 Results, Cites Going Concern Uncertainty Amidst Pipeline Development Efforts

Mosaic ImmunoEngineering's Q1 2025 report reveals a net loss of $181,320 and raises concerns about the company's ability to continue as a going concern due to limited cash and the need for additional financing.

Summary

• Mosaic ImmunoEngineering, Inc. reported its financial results for the quarter ended March 31, 2025.
• The company is a development-stage biotechnology company focused on advancing immunotherapies for cancer treatment.
• For Q1 2025, the company reported a net loss of $181,320, compared to a net loss of $288,492 for the same period in 2024.
• Research and development expenses were $15,803, a decrease from $67,311 in the prior year's quarter.
• General and administrative expenses were $158,971, down from $201,455 in Q1 2024.
• The company had cash and cash equivalents of $85,930 as of March 31, 2025.
• Mosaic ImmunoEngineering has not yet generated any revenues.
• The report indicates that the company's ability to continue operations is highly dependent on raising additional capital.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company is pursuing a potential transaction with Oncotelic Therapeutics, Inc. to acquire new technologies and secure short-term funding, but there are no guarantees a definitive agreement will be reached.
• The company entered into a Master Services Agreement with Oncotelic whereby the company performs advisory and related services in connection with studies and projects, earning $14,000 for the quarter.
• The company received $200,000 under an unsecured convertible note purchase agreement in December 2024.

Sentiment

Score: 3

Explanation: The sentiment is low due to the company's financial instability, dependence on external funding, and the uncertainty surrounding the Oncotelic transaction. While there are some positive aspects, such as decreased losses and expenses, the overall outlook is concerning.

Positives

• The net loss decreased from $288,492 in Q1 2024 to $181,320 in Q1 2025.
• Research and development expenses decreased by approximately $52,000 compared to the same period last year.
• General and administrative expenses decreased by approximately $42,000 compared to the same period last year.
• The company has a binding term sheet with Oncotelic Therapeutics, potentially providing access to new technologies and funding.
• The company is generating some revenue through a Master Services Agreement with Oncotelic, earning $14,000 in Q1 2025.

Negatives

• The company reported a net loss of $181,320 for Q1 2025.
• The company's cash and cash equivalents are low, at $85,930 as of March 31, 2025.
• The company has not generated any revenues from its core business.
• The company's ability to continue operations is highly dependent on raising additional capital, with no current arrangements in place.
• There is substantial doubt about the company's ability to continue as a going concern.
• The potential transaction with Oncotelic is subject to shareholder approval and other conditions, with no guarantee of completion.
• If the transaction with Oncotelic proceeds, current stockholders will experience immediate substantial dilution and will not have control of the majority voting securities.

Risks

• The company's limited cash position raises substantial doubt about its ability to continue as a going concern.
• The company's dependence on raising additional capital creates uncertainty about its future operations.
• The potential transaction with Oncotelic is subject to various conditions and may not be completed.
• If the Oncotelic transaction proceeds, existing shareholders will face significant dilution.
• Failure to obtain shareholder approval for the Oncotelic transaction could lead to the cessation of operations.
• Economic factors, such as COVID-19 disruptions, inflation, and a potential recession, could negatively impact the company's ability to raise capital.
• The company's limited development activities and scaled-back programs due to its cash position could hinder its progress.
• The company may be involved in various lawsuits and claims arising in the ordinary course of business, including actions with respect to intellectual property, employment, and contractual matters.

Future Outlook

The company's future is highly dependent on its ability to raise additional capital and the potential transaction with Oncotelic Therapeutics. The company anticipates that its cash on hand will not satisfy its operational and capital requirements through twelve months from the filing date of this report. If the Oncotelic transaction is completed, the company expects to continue development work necessary to achieve mutually agreed upon milestones upon the requisite funding.

Management Comments

• Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives.
• Management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.
• Management has determined that no other subsequent events have occurred that would require recognition in the accompanying unaudited condensed consolidated financial statements or disclosure in the notes thereto other than as disclosed in the accompanying notes.

Industry Context

As a development-stage biotechnology company, Mosaic ImmunoEngineering operates in a high-risk, high-reward sector. The company's focus on immunotherapies for cancer treatment aligns with a growing trend in the pharmaceutical industry. However, the company's financial situation and dependence on external funding are significant challenges in a competitive landscape.

Comparison to Industry Standards

• It is difficult to compare Mosaic ImmunoEngineering to industry standards due to its early stage of development and lack of revenue.
• Many comparable companies are private and do not disclose financial information.
• Publicly traded biotechnology companies with similar market capitalizations often have more advanced clinical programs and greater access to capital.
• For example, companies like VBI Vaccines Inc. and Celldex Therapeutics, Inc. are also focused on immunotherapies and have ongoing clinical trials, but have significantly more cash on hand.
• Mosaic's reliance on convertible notes and potential reverse merger with Oncotelic are atypical strategies compared to industry norms of venture capital funding and IPOs.

Related Party Transactions

• During April 2021, the company entered into consulting agreements (retroactive to September 1, 2020) with Nicole Steinmetz, Jonathan Pokorski, and Steve Fiering, each a co-founder of the company acquired in the reverse merger and greater than 5% shareholder of the Company (Related Parties), for their scientific contributions towards advancing the technology platforms.
• On May 7, 2021, the company entered into convertible note purchase agreements with five (5) accredited investors, including three (3) members of the Board of Directors that participated on the same terms as other accredited investors, in the aggregate principal amount of $575,000.
• On February 18, 2022, the company entered into convertible note purchase agreements with sixteen (16) accredited investors, including five (5) members of the Board that participated on the same terms as other accredited investors, in the aggregate principal amount of $341,632.
• Mr. Steven King, the company's president and CEO, is a shareholder and member of the board of directors of Oncotelic with less than 1% ownership of total shares outstanding of Oncotelic, and a paid advisor of Oncotelic.

Stakeholder Impact

• Shareholders face significant dilution if the Oncotelic transaction proceeds.
• Employees face uncertainty due to the company's financial instability and potential cessation of operations.
• Creditors face risk of non-payment due to the company's limited cash position.
• Suppliers may be impacted by the company's potential inability to fulfill its obligations.

Next Steps

• The company needs to secure additional funding to continue operations.
• The company must negotiate and finalize a definitive agreement with Oncotelic Therapeutics.
• The company needs to obtain shareholder approval for the potential transaction with Oncotelic.
• The company needs to receive waivers from holders of Convertible Notes representing at least 90% of the principal amount outstanding from any payment that would become due and payable upon a corporate transaction as contemplated under the Binding Term Sheet.
• The company will continue the development work necessary to achieve the mutually agreed upon milestones upon the requisite funding.

Key Dates

Keywords

ImmunoEngineering, Biotechnology, Immunotherapies, Cancer, Financial Results, Going Concern, Oncotelic, Acquisition, Convertible Notes, Capital Raise